Next generation small animal radiation research platform

下一代小动物辐射研究平台

• 批准号: 10680056
• 负责人: Xun Jia
• 金额: $ 15.88万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10680056
• 关键词: Address; Algorithms; Anesthesia procedures; Animals; Clinic; Clinical; Clinical Research; Clinical Treatment; Collimator; Communities; Computational Technique; Computer software; Cost Analysis; Development; Development Plans; Dose; Engineering; Ensure; Freedom; Functional Imaging; Generations; Hour; Human; Hypoglycemia; Image; Immune response; Impairment; Intensity-Modulated Radiotherapy; Interruption; Intuition; Investigation; Joints; Learning; Lung; Malignant Neoplasms; Manuals; Mechanics; Medical; Medical center; Modality; Modernization; Normal tissue morphology; Organ; Physiological; Positron-Emission Tomography; Price; Process; Radiation; Radiation Dose Unit; Radiation therapy; Radiobiology; Radiotherapy Research; Rattus; Research; Resources; Risk; Sales; Sample Size; Shapes; Side; Software Design; Speed; System; Techniques; Technology; Testing; Therapeutic; Time; Tissues; Translating; Translations; Validation; anatomic imaging; base; cone-beam computed tomography; cost; design; design and construction; evidence base; experience; frontier; image guided; imaging modality; imaging platform; improved; industry partner; innovation; natural hypothermia; next generation; novel; pre-clinical; pre-clinical research; preclinical study; product development; programs; prototype; reconstruction; research study; response; systems research; treatment planning; treatment response; tumor

PROJECT SUMMARY Small Animal Radiation Research (SARR) is of paramount importance for the advancement of human radiotherapy (RT) by serving as a critical counterpart to perform comprehensive preclinical studies on a large number of subjects under controlled experimental conditions at low costs. SARR relies on dedicated platforms to administer radiation dose to animals in a similar way as in the clinic. Current-generation SARR irradiators, developed in the past decade, have failed to keep pace with technology advancements in human RT. In stark contrast to modern RT treatments where novel anatomical and functional imaging, inverse treatment planning, and intensity modulated delivery techniques are routinely employed to precisely form an extremely conformal dose distribution to the tumor, the therapeutic form in current SARR systems resembles an obsolete form of human RT. This technology disparity has substantially impaired SARR study relevance to human RT, impeded explorations in RT research, and hindered rapid conduction of SARR studies. Towards addressing this problem, in response to PAR-15-075, this project will develop and translate a next-generation SARR platform through an academic-industrial partnership, joining medical physicists and radiobiologists at UT Southwestern Medical Center (UTSW) with engineering experts at Faxitron Bioptics LLC (Faxitron). The developed system will be substantially superior to the current state-of-the-art SARR platform due to its novel imaging methods (dual energy cone beam CT and PET), intensity modulated radiotherapy, and high computation and treatment delivery efficiency. These novel features are expected to improve SARR research relevance to human RT by delivering treatments of clinical quality, to support exploration in modern RT by offering technical freedom to realize novel imaging and therapy approaches, and to increase research efficiency by enhancing computational speed and workflow. We will perform studies with the following specific aims (SAs): SA1: Refine hardware design and construct the hardware system including mechanical, imaging, and therapy subsystems. SA2: Refine software design and develop an imaging and treatment planning system accompanied with the hardware platform. SA3: Perform comprehensive system tests, develop a translation plan, and demonstrate achieved advantages of the system via an animal study on image-guided intensity-modulated lung stereotactic body radiotherapy using rats. The innovation of this project includes novel technological capabilities enabled by the next-generation SARR platform, as well as coherent translation activities to deliver new capabilities to end- users. Project feasibility is ensured by extensive preliminary studies, and the research team integrating medical physicists and radiobiologists (UTSW) with strong clinical and research expertise and engineers (Faxitron) with extensive commercial product development experience. By filling the critical void between SARR and human RT, the developed system will become an essential component in preclinical research for the exploration of novel radiotherapeutic strategies with high relevance to human RT.

项目摘要 小动物辐射研究（SARR）对于人类的发展至关重要 放疗（RT）通过作为对大型临床前研究的关键对应 在受控的实验条件下以低成本为单位的受试者数量。 Sarr依靠专用平台 以与诊所相似的方式给动物施加辐射剂量。当前的萨尔辐照人， 在过去的十年中，开发的发展未能与人类RT的技术进步保持同步。在斯塔克 与现代的RT治疗形成对比，新的解剖和功能成像，逆处理计划， 和强度调制的交付技术通常用于精确形成极端形成 肿瘤的剂量分布，当前Sarr系统中的治疗形式类似于过时的形式 人Rt。这种技术差异严重损害了与人类RT有关的Sarr研究，并阻碍了 RT研究的探索，并阻碍了Sarr研究的快速传导。要解决这个问题 问题，响应于15-075 Par，该项目将开发和翻译下一代Sarr平台 通过学术工业合作伙伴关系，加入UT西南部的医学物理学家和放射性生物学家 Faxitron Bioptics LLC（Faxitron）的工程专家医疗中心（UTSW）。开发的系统 由于其新型成像方法，将大大优于当前的最新Sarr平台 （双能锥束CT和PET），强度调节放射疗法以及高计算和处理 交付效率。这些新颖的功能有望通过 通过提供技术自由来提供临床质量的治疗，以支持现代RT的探索 实现新颖的成像和治疗方法，并通过提高研究效率 计算速度和工作流程。我们将使用以下特定目标（SAS）进行研究：SA1：完善 硬件设计和构建硬件系统，包括机械，成像和治疗子系统。 SA2：完善软件设计并开发成像和治疗计划系统以及 硬件平台。 SA3：执行全面的系统测试，制定翻译计划并演示 通过动物研究对图像引导强度调节的肺立体定向，实现了系统的优势 使用大鼠的身体放射疗法。该项目的创新包括由新的技术能力启用 下一代Sarr平台以及连贯的翻译活动，以提供新的功能，以实现最终功能 用户。通过广泛的初步研究确保项目可行性，并整合医学的研究团队 具有强大临床和研究专业知识和工程师（Faxitron）的物理学家和放射性生物学家（UTSW） 丰富的商业产品开发经验。通过填补萨尔和人之间的关键空隙 RT，开发的系统将成为临床前研究的重要组成部分，以探索 与人RT相关的新型放射治疗策略。